Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Dako CDx for Merck's NSCLC Test

NEW YORK (GenomeWeb) – Agilent Technologies' Dako today said that the US Food and Drug Administration has approved the firm's companion diagnostic assay in connection with a simultaneous approval for Merck's non-small lung cancer drug. 

The companion diagnostic called PD-L1 IHC 22C3 pharmDx is used to determine whether a patient with advanced NSCLC is likely to respond to Merck's anti-PD-1 therapy Keytruda (pembrolizumab), which was approved by the FDA for treating patients with metastatic NSCLC whose tumors expressed PD-L1 and whose disease has progressed on or after platinum-containing chemotherapy. 

Dako's test, developed in partnership with Merck, will be used to determine whether the patient's tumor expresses the PD-L1 protein. Dako said that it hopes to gain regulatory clearance for the assay in Canada, Europe, and other jurisdictions next year. 

"The approval of the first PD-L1 diagnostic has the potential to provide information that will help guide treatment decisions for many patients," Roger Dansey, senior vice president at Merck Research Laboratories, said in a statement. 

Dako and Merck announced a deal to develop a CDx for Keytruda in May 2014.

Separately, Labortory Corporation and Quest Diagnostics each said that they will provide clinical laboratory testing using PD-L1 IHC 22C3 pharmDx. Physicians are able to order the test from either firms starting today. Also, GE Healthcare's Clarient is offering the test. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.